+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bladder Cancer Drugs Market by Drug Class, Mechanism Of Action, Line Of Therapy, Administration Route, Distribution Channel - Global Forecast to 2030- Product Image
Bladder Cancer Drugs Market by Drug Class, Mechanism Of Action, Line Of Therapy, Administration Route, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Bladder Cancer Drugs Market by Drug Class, Mechanism Of Action, Line Of Therapy, Administration Route, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010936
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The bladder cancer drugs market is rapidly redefining standards in oncology with the emergence of immunotherapy, novel targeted therapies, and digital health integration. For senior decision-makers, navigating this evolving competitive environment requires precise insight into market drivers, regulatory shifts, and differentiated innovation.

Market Snapshot: Bladder Cancer Drugs Market

In 2024, the Bladder Cancer Drugs Market was valued at USD 2.12 billion, rising to USD 2.47 billion in 2025. Future growth is projected at a CAGR of 15.87%, with the market expected to reach USD 5.14 billion by 2030.

Scope & Segmentation

This research provides actionable segmentation and coverage of the evolving bladder cancer drug landscape, addressing therapeutics, mechanisms, and regional dynamics.

  • Drug Classes: Chemotherapy; Immunotherapy (Immune Checkpoint Inhibitors, Monoclonal Antibodies); Targeted Therapy (FGFR Inhibitors, Tyrosine Kinase Inhibitors)
  • Mechanisms of Action: Antibody Drug Conjugates (Approved, Clinical Development); FGFR Inhibitors (Approved, Clinical Development); PD-1 Inhibitors (Approved, Clinical Development); Tyrosine Kinase Inhibitors (Approved, Clinical Development)
  • Line of Therapy: First Line (Combination Therapy, Monotherapy); Second Line (Combination Therapy, Monotherapy); Third Line (Combination Therapy, Monotherapy)
  • Administration Route: Intravenous (Bolus, Infusion); Intravesical (Liquid Instillation); Oral (Capsule Tablets, Solution)
  • Distribution Channels: Hospital Pharmacy (Academic Medical Center, Community Hospital); Retail Pharmacy (Chain Pharmacy, Independent Pharmacy); Specialty Pharmacy
  • Regional Coverage: Americas (including the United States, Canada, Brazil, Mexico, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, UAE, South Africa, and others); Asia-Pacific (including China, India, Japan, Australia, South Korea, and more).
  • Key Companies Reviewed: Merck & Co., F. Hoffmann-La Roche, Pfizer, Merck KGaA, AstraZeneca, Bristol-Myers Squibb, Astellas Pharma, Johnson & Johnson, Seagen

Key Takeaways

  • Immuno-oncology and precision medicine are rapidly altering first-line and subsequent therapies, shifting the competitive balance and enabling patient stratification based on genomic or immune profile.
  • The diversity in therapeutic classes and mechanisms of action highlights the need for targeted pipeline investments and robust portfolio management to capture emerging opportunities in both established and novel drug segments.
  • Digital platforms and remote monitoring improve treatment adherence and enable real-world evidence collection, supporting clinical and health economic value demonstration for stakeholders.
  • Market access strategies must reflect local dynamics—advanced economies provide fertile ground for innovation, while emerging markets require adaptive pricing and local partnerships to address affordability and access barriers.
  • Collaborative trends, including cross-sector partnerships and licensing agreements, are pivotal in translating academic innovation into late-stage pipelines and expanding commercial footprints.

Tariff Impact

Recent United States tariff changes have increased production costs for drug manufacturers by imposing higher duties on imported pharmaceutical ingredients. In response, companies have adjusted supply chain strategies, explored regional sourcing, and renegotiated contracts. These changes have necessitated balancing organizational margins against payer affordability, especially for high-value, innovative therapies. Manufacturers are leveraging health economics evidence and negotiating with regulators to maintain patient access and mitigate risks related to fluctuating trade policies.

Methodology & Data Sources

The analysis leverages secondary research from peer-reviewed medical literature, regulatory submissions, and clinical trial registries, supplemented by primary interviews with oncology experts, payers, and patient representatives. Quantitative data validation, triangulation, and competitive benchmarking ensure the accuracy and contextual clarity required for confident decision-making.

Why This Report Matters

  • Enables executive-level insight into competitive, regulatory, and technological factors shaping the bladder cancer drugs market.
  • Supports portfolio optimization and go-to-market strategies with targeted market access, regional focus, and segment prioritization.
  • Delivers a comprehensive foundation for due diligence, forecasting, and partnership evaluation in both mature and emerging economies.

Conclusion

With a dynamic landscape and increasing differentiation in therapies, the bladder cancer drugs market demands informed strategic planning. Stakeholders who adapt to changing technologies, regulatory frameworks, and regional access will be positioned to capture value and improve patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bladder Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.3.1. Immune Checkpoint Inhibitors
8.3.2. Monoclonal Antibodies
8.4. Targeted Therapy
8.4.1. FGFR Inhibitors
8.4.2. Tyrosine Kinase Inhibitors
9. Bladder Cancer Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Antibody Drug Conjugate
9.2.1. Approved
9.2.2. Clinical Development
9.3. FGFR Inhibitor
9.3.1. Approved
9.3.2. Clinical Development
9.4. PD-1 Inhibitor
9.4.1. Approved
9.4.2. Clinical Development
9.5. Tyrosine Kinase Inhibitor
9.5.1. Approved
9.5.2. Clinical Development
10. Bladder Cancer Drugs Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.2.1. Combination Therapy
10.2.2. Monotherapy
10.3. Second Line
10.3.1. Combination Therapy
10.3.2. Monotherapy
10.4. Third Line
10.4.1. Combination Therapy
10.4.2. Monotherapy
11. Bladder Cancer Drugs Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.2.1. Bolus
11.2.2. Infusion
11.3. Intravesical
11.3.1. Liquid Instillation
11.4. Oral
11.4.1. Capsule Tablets
11.4.2. Solution
12. Bladder Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. Academic Medical Center
12.2.2. Community Hospital
12.3. Retail Pharmacy
12.3.1. Chain Pharmacy
12.3.2. Independent Pharmacy
12.4. Specialty Pharmacy
13. Americas Bladder Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bladder Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bladder Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. F. Hoffmann-La Roche Ltd
16.3.3. Pfizer Inc.
16.3.4. Merck KGaA
16.3.5. AstraZeneca PLC
16.3.6. Bristol-Myers Squibb Company
16.3.7. Astellas Pharma Inc.
16.3.8. Johnson & Johnson
16.3.9. Seagen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BLADDER CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BLADDER CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BLADDER CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BLADDER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BLADDER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLADDER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY LIQUID INSTILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CAPSULE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY ACADEMIC MEDICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLADDER CANCER DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BLADDER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 108. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 111. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 112. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 113. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 114. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 116. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 118. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 119. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 120. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 121. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 122. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 123. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 124. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. CANADA BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 223. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 226. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 228. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 229. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 230. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 231. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 232. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 233. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 234. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 236. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 239. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 241. GERMANY BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 243. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 244. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 245. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 246. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 247. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 248. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 249. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 250. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 251. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 252. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 253. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 254. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 255. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 256. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 257. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. FRANCE BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 280. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 282. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 283. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 285. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 286. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 287. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 288. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 289. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 290. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 291. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 292. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 293. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 294. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 295. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 296. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 298. ITALY BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 299. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 302. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 303. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 304. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 305. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 306. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 307. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 308. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 309. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 310. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 311. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 313. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY INTRAVESICAL, 2018-2030 (USD MILLION)
TABLE 314. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 315. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 317. SPAIN BLADDER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY FGFR INHIBITOR, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES BLADDER CANCER DRUGS MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bladder Cancer Drugs market report include:
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck KGaA
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Seagen Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.14 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Bladder Cancer Therapeutics Market by Therapeutic Approach, Treatment Stage, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Bladder Cancer Therapeutics Market by Therapeutic Approach, Treatment Stage, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Bladder Cancer Pipeline Analysis Report - Product Image

Bladder Cancer Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 265 Pages
  • Global
From
Metastatic Urothelial Carcinoma Global Market Report 2025 - Product Image

Metastatic Urothelial Carcinoma Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From

About the Bladder Cancer Drugs Market

The Bladder Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat bladder cancer. Bladder cancer is a type of cancer that affects the urinary tract and is the sixth most common type of cancer in the United States. Common treatments for bladder cancer include chemotherapy, radiation therapy, and surgery. Drugs used to treat bladder cancer are typically classified as either targeted therapies or immunotherapies. Targeted therapies are designed to target specific molecules or pathways in the body that are involved in the growth and spread of cancer cells. Immunotherapies are designed to stimulate the body’s own immune system to fight cancer cells. Some of the major companies in the Bladder Cancer Drugs market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development and sale of drugs used to treat bladder cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.